Effect of CPL-2009-0031 in the Treatment of Patients With Uncontrolled Type 2 Diabetes Mellitus

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

355 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-01-26

Study Completion Date

2021-02-11

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This trial is a Phase-III, Prospective, Randomized, Double Blind, Parallel Group, Two arm, Comparative, Multicenter, controlled clinical trial to determine the efficacy, safety, and tolerability of oral CPL-2009-0031 140 mg in comparison with Sitagliptin 100 mg in patients with Uncontrolled Type-2 Diabetes Mellitus (T2DM).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Sitagliptin Dose Comparison Study in Patients With Type 2 Diabetes (MK-0431-077)(COMPLETED)

NCT00541229

Type 2 Diabetes

COMPLETED PHASE1

Efficacy and Safety of CWP-0403 Compared to Sitagliptin in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled With Metformin Alone

NCT01529541

Type 2 Diabetes Mellitus

COMPLETED PHASE3

Sitagliptin in Prevention of Type 2 Diabetes Mellitus

NCT01038648

Type 2 Diabetes

WITHDRAWN PHASE3

A Study of an Investigational Drug Sitagliptin for Type 2 Diabetes Mellitus (0431-044)

NCT00127192

Type 2 Diabetes Mellitus

COMPLETED PHASE2

Study of Chiglitazar Compare With Sitagliptin in Type 2 Diabetes Patients

NCT02173457

Type 2 Diabetes

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In this phase-III trial, after due consent and completing initial 2-weeks of placebo run-in period with diet, exercise and counseling, eligible patients with uncontrolled T2DM will be randomized in balance to receive either once daily oral CPL-2009-0031 140 mg or Sitagliptin 100 mg.

After completing 12 weeks of study post-randomization for regulatory submission, patients will be instructed for continuation of extension phase of treatment and follow up upto 36 weeks.

HbA1c will be measured at screening, baseline, 12 weeks, 24 weeks and 36 weeks of treatment. While, Fasting Blood Sugar (FBS) and Postprandial Blood Sugar (PPBS) measurement will be performed every 2 weeks.

The enrolled patients will be monitored for safety (AE and SAE) throughout the study period.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Uncontrolled Type 2 Diabetes Mellitus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Prospective, Randomized, Double Blind, Parallel Group, Two arm, Comparative, Multicenter, controlled study

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Investigator, patient, study staff, data monitors and database personnel will be blinded to the study treatment.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

CPL-2009-0031 140 mg

Single dose, Oral tablet containing 140 mg of CPL-2009-0031, Once daily for 36-weeks

Group Type EXPERIMENTAL

CPL-2009-0031 140 mg

Intervention Type DRUG

Patients will receive OD CPL-2009-0031 140 mg for 36 weeks with or without breakfast with a glass of water.

Sitagliptin 100 mg

Single dose, Oral tablet containing 100 mg of Sitagliptin, Once daily for 36-weeks

Group Type ACTIVE_COMPARATOR

Sitagliptin 100mg

Intervention Type DRUG

Patients will receive OD Sitagliptin 100 mg for 36 weeks with or without breakfast with a glass of water.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CPL-2009-0031 140 mg

Patients will receive OD CPL-2009-0031 140 mg for 36 weeks with or without breakfast with a glass of water.

Intervention Type DRUG

Sitagliptin 100mg

Patients will receive OD Sitagliptin 100 mg for 36 weeks with or without breakfast with a glass of water.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male and female adult patient of 18-65 years with uncontrolled type 2 diabetes Mellitus (T2DM).
* Patients with HbA1c ≥ 7 to 10 and those on oral hypoglycemic agents ≤ 2 other than Insulin and Gliptins.
* BMI in the range of 18.5 - 35 kg/m2.
* All patients must be willing to give informed consent and can understand \& complying protocol requirement.
* Patients who are in good health at the time of entry into the study as determined by medical, medication and hypersensitivity histories, clinical examination, vital sign measurements, chest X-ray, 12-lead ECG measurement and clinical judgment of the investigator.
* Documented negative test for human immuno virus (HIV), Hepatitis B surface antigen (HBsAg) and Hepatitis C virus (HCV).

Exclusion Criteria

* Those who are on insulin and not ready for wash out of 3 months.
* Those who are on gliptin and not ready for wash out of 3 months.
* Those with a history of severe ketosis, diabetic coma or pre-coma, or type 1 diabetes.
* Those scheduled for or who had undergone surgery.
* Those with a severe infection or serious injury
* Pregnant and lactating women.
* Hypersensitivity and contraindication to DPP-IV inhibitors or excipients of investigational drug formulation.
* Hypertensive patients with blood pressure ≥160/100 mm of Hg.
* History of ischemic heart disease (as evident from ECG), stroke and/or transient ischemic attack.
* Debilitating neurological or psychiatric disorders
* History or currently consuming abusing drugs or alcohol.
* Serious hepatic or renal impairment (liver dysfunction as evidenced by SGPT/SGOT level of 2.5 X ULN and renal dysfunction as evidenced by creatinine level 2.5 X ULN).
* Patient with abnormal clinical chemistry, hematology or urinalysis results that are considered clinically significant by the investigator or the sponsor.
* Patient has any concurrent illness which, in the opinion of the investigator or coinvestigator, may interfere with treatment or evaluation of safety or completion of this study.
* In the investigator's judgment, the patient is unable to adhere to the treatment regimen, protocol procedures or study requirements.
* Participation in another clinical trial in the past 3 months.
* Patients with history of smoking or currently having smoking habit will not be included in the study.

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No